Goldline Pharmaceutical Limited’s equity shares (Scrip Code: 544759, ISIN: INE1CLW01015) will be listed on the BSE SME platform effective Tuesday, May 19, 2026, under the ‘MT’ Group of Securities. In accordance with SEBI circular CIR/MRD/DP/02/2012, the scrip will trade in the Trade-for-Trade segment for the first 10 trading days.

Key Points

• Listing Date: Tuesday, May 19, 2026
• Scrip ID / Abbreviated Name: GLPL
• Scrip Code: 544759
• ISIN: INE1CLW01015
• Total Securities: 9,600,000 equity shares of Rs. 10/- each, fully paid up
• Distinctive Number Range: 1 to 9,600,000
• Issue Price: Rs. 43/- per share (Face Value Rs. 10/- + Premium Rs. 33/-)
• Market Lot: 3,000 equity shares
• Date of Allotment: May 15, 2026
• Group: MT Group (SME segment)
• Trade-for-Trade segment: First 10 trading days
• Trading only in dematerialised form per SEBI guidelines dated February 16, 2000

Regulatory Changes

No new regulatory changes introduced. Listing is conducted under existing SEBI circular CIR/MRD/DP/02/2012 (dated January 20, 2012) which mandates Trade-for-Trade segment for new SME listings for 10 trading days.

Compliance Requirements

• Trading members must trade the scrip only in dematerialised form.
• Trades must be executed in the minimum market lot of 3,000 equity shares; this may be modified by the Exchange with at least one month’s prior notice.
• The scrip will participate in the Special Pre-open Session (SPOS) on May 19, 2026; members should refer to Exchange notice 20120216-29 dated February 16, 2012 for SPOS details.
• Lock-in period has been marked in depository records for shares in demat form.

Important Dates

• May 15, 2026: Date of allotment in the public issue
• May 19, 2026: Listing date and first day of trading; SPOS participation
• 10 trading days from May 19, 2026: Trade-for-Trade segment restriction period

Impact Assessment

This is a standard SME IPO listing with moderate market impact. The Trade-for-Trade restriction for 10 days limits speculative intraday trading, reducing volatility risk in the early trading period. The market lot size of 3,000 shares limits retail participation to investors with meaningful capital. The Market Maker is Nirman Share Brokers Private Limited, which is responsible for providing liquidity. Trading members and investors holding allotted shares should note the SPOS requirement on the first trading day. Overall impact is limited to SME segment participants and IPO allottees.

BSE Limited has issued a notice informing trading members that the equity shares of Goldline Pharmaceutical Limited will be listed and admitted to dealings on the Exchange. The specific listing date and further security details will be communicated through a separate notice.

Key Points

• Goldline Pharmaceutical Limited equity shares will be listed on the BSE SME segment.
• Scrip Code: 544759 | Symbol: GLPL | ISIN: INE1CLW01015
• The exact listing date has not yet been announced; a separate notice will follow.
• Notice issued by Hardik Bhuta, Assistant Vice President, BSE Limited.

Regulatory Changes

No regulatory changes introduced. This is a standard pre-listing information notice.

Compliance Requirements

Trading members should note the scrip details (code 544759, symbol GLPL, ISIN INE1CLW01015) and await the subsequent notice confirming the listing date before initiating any dealings.

Important Dates

• Notice Date: 18 May 2026
• Listing Date: To be announced via a separate notice

Impact Assessment

Limited market-wide impact. This notice concerns a single SME-segment listing and is informational in nature. Investors interested in Goldline Pharmaceutical Limited should monitor BSE for the follow-up notice confirming the listing date and trading commencement details.